Accutar Biotechnology Announces First Patient Dosed with AC0682 in Phase 1 Study in Patients with ER-Positive / HER2-Negative Locally Advanced or Metastatic Breast Cancer

– Differentiated Mechanism of Action by Chimeric Degrader vs. Fulvestrant and Novel SERDs –

– ERα Wildtype & Mutant Coverage to Overcome Resistance –

– Blood-Brain Barrier Penetration to Address Brain Metastases –

BROOKLYN, N.Y.--(BUSINESS WIRE)--Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, today announced the dose administration for the first patient in a Phase 1 study of AC0682, an orally bioavailable, chimeric degrader molecule designed to target and degrade ERα protein with high potency and selectivity.

"The initiation of this study represents a significant milestone for Accutar, as it marks the first program from our AI-enabled drug discovery platform and our chimeric degrader portfolio to enter the clinic," said Jie Fan, Ph.D., Chief Executive Officer of Accutar Biotechnology, Inc. "We look forward to the clinical benefit that AC0682 treatment can potentially provide to ER-positive breast cancer patients.”

The purpose of the Phase 1 multi-center, open-label study is to assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of AC0682 treatment in patients with ER-positive / HER2-negative locally advanced or metastatic breast cancer. Additional information on this clinical trial can be found on www.clinicaltrials.gov.

About AC0682

AC0682 is an investigational orally bioavailable, chimeric degrader of estrogen receptor (ER) α for the potential treatment of ER-positive / human epidermal growth factor receptor 2 (HER2)-negative breast cancers. In preclinical studies, AC0682 has demonstrated potent and selective protein degradation of ERα wildtype and mutants with favorable pharmacological properties and brain penetration, as well as promising anti-tumor activities in ER-positive animal tumor models. AC0682 offers a potential new breast cancer treatment based on a differentiated mechanism of action from fulvestrant and novel SERDs.

About Accutar Biotechnology, Inc.

Accutar is a clinical stage biotech company focused on AI-enabled drug discovery, and its application to the discovery and development of clinically differentiated medicines.

Be transformative. For patients.

To learn more about Accutar, please visit us at www.accutarbio.com.

Jiaqi Ren
media@accutarbio.com